Haifa Kathrin Al-Ali

Haifa Kathrin Al-Ali leads the German and European MPN registry programs that have generated critical real-world data on MPN epidemiology, treatment patterns, and outcomes. Her registry analyses have provided external validation of clinical trial findings with ruxolitinib and second-generation JAK inhibitors across diverse patient populations. She has contributed to understanding polycythemia vera transformation to myelofibrosis and AML. Her translational research bridges laboratory discoveries with clinical outcomes data from large patient cohorts.